Clinical Trial Update: Ipilumumab and Nivolumab With or Without Hypofractionated Radiotherapy in Patients With Metastatic Melanoma [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial at Penn Medicine evaluating ipilimumab and nivolumab with or without hypofractionated radiotherapy in patients with metastatic melanoma…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• ipilimumab (ipilimumab)
• nivolumab (nivolumab)

Snippet

Sponsor: Abramson Cancer Center at Penn Medicine | Conditions: Metastatic Melanoma | Phase 2 | Status: RECRUITING